US 6,441,193 B1 · Estrogen agonists/antagonists

Abstract

Compounds of this formula are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.

Claims3

Dependent claims

The compound 1-{2-[4-(6-Methoxy-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl}pyrrolidine.

Dependencies are inferred from the claim text.

Facts

Application

09/466,034Filed 17 Dec 1999 · continuation

Priority

9 Jan 1995

Granted

27 Aug 2002

Term ends

Not estimatedThe source records don’t support an estimate.

Classification16 codes

C07D 213/64
One oxygen atom: attached in position 2 or 6
A61K 31/40
Having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins: having five-membered rings with one nitrogen as the only ring hetero atom,…
A61P 3/06
Drugs for disorders of the metabolism: antihyperlipidemics
A61P 5/00
Drugs for disorders of the endocrine system

Family

Application08/369,954Parent of this continuation · filed 9 Jan 1995

PCT/IB95/00286Parent of this continuation · filed 24 Apr 1995

Application08/849,726Parent of this continuation

US 6,204,286 B1Parent of this continuation

US 5,552,412 AParent of this continuation

US 6,441,193 B1This patent

From the US filing history. Foreign family members aren’t listed.

Abstract

Compounds of this formula are useful for treating or preventing, obesity, breast cancer, osteoporosis, endometriosis, cardiovascular disease and prostatic disease.

Estrogen agonists/antagonists

Life of this patent

Abstract

Claims3

Estrogen agonists/antagonists

Life of this patent

Abstract

Claims3